Logo

ATYR

aTyr Pharma, Inc.

ATYR

aTyr Pharma, Inc. • NASDAQ
$0.78 ▲ 2.21% (+0.02)
Market Cap $76.64 M
52w High $7.29
52w Low $0.64
Dividend Yield 0%
P/E -0.92
Volume 977.58K
Outstanding Shares 97.99M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $190K ▲ $4.805M ▼ $-25.744M ▼ -13.549K% ▼ $-0.26 ▼ $-25.581M ▼
Q2-2025 $0 $20.313M ▲ $-19.531M ▼ 0% $-0.22 ▼ $-19.926M ▼
Q1-2025 $0 $15.773M ▲ $-14.88M ▲ 0% $-0.17 ▲ $-15.39M ▲
Q4-2024 $0 $3.592M ▼ $-14.967M ▲ 0% $-0.18 ▲ $-15.645M ▲
Q3-2024 $0 $18.143M $-17.259M 0% $-0.23 $-17.755M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $90.202M ▲ $106.652M ▲ $26.608M ▼ $80.235M ▲
Q2-2025 $80.346M ▲ $101.534M ▲ $26.878M ▲ $74.845M ▼
Q1-2025 $76.349M ▲ $97.245M ▲ $22.383M ▼ $75.05M ▲
Q4-2024 $72.125M ▲ $96.83M ▲ $26.998M ▲ $70.019M ▲
Q3-2024 $65.987M $91.616M $26.477M $65.325M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-25.746M ▼ $-20.476M ▼ $-20.377M ▼ $29.617M ▲ $-11.236M ▼ $-20.513M ▼
Q2-2025 $-19.532M ▼ $-13.894M ▲ $3.301M ▲ $17.897M ▼ $7.304M ▲ $-13.903M ▲
Q1-2025 $-14.881M ▲ $-15.42M ▼ $-4.42M ▲ $18.628M ▼ $-1.212M ▼ $-15.42M ▼
Q4-2024 $-14.968M ▲ $-13.132M ▲ $-6.085M ▼ $18.839M ▲ $-378K ▼ $-13.157M ▲
Q3-2024 $-17.259M $-13.158M $17.946M $-105K $4.683M $-13.173M

Five-Year Company Overview

Income Statement

Income Statement aTyr is essentially a pre‑revenue biotech. Over the past several years it has generated almost no product or licensing revenue, while consistently recording operating and net losses. This pattern is typical for a clinical‑stage company that is funding R&D and trials without any approved products. Losses appear relatively stable in recent years rather than rapidly worsening, but the business model is still firmly in the spend‑to‑develop phase rather than the earn‑from‑sales phase. Profitability is not in sight until at least one drug is approved and commercialized or significant partnering income appears.

Balance Sheet

Balance Sheet The balance sheet is small and lean, with a modest base of assets and shareholder equity. Cash is present but not abundant relative to the costs of late‑stage clinical development, and there is a small amount of debt. Overall leverage looks limited, which reduces balance‑sheet risk, but the company’s resources are clearly finite. aTyr’s ability to sustain operations and fund its pipeline will depend heavily on continued access to capital markets, milestone payments, or additional partnerships rather than internal cash generation.

Cash Flow

Cash Flow Cash flows reflect a classic development‑stage biotech profile: operating cash flow has been consistently negative as the company spends on research, clinical trials, and overhead, while capital spending is negligible. Free cash flow is therefore firmly negative, and the business is reliant on external financing to replenish cash. The key question for investors is how long existing cash can support current trial programs and how much additional funding may be required as pivotal and follow‑on studies progress.

Competitive Edge

Competitive Edge aTyr is positioned in a specialized niche of immunology and fibrosis, built around the extracellular biology of tRNA synthetases—a space with few direct peers. Its lead drug, efzofitimod, targets a novel receptor and aims to modulate the immune system in a more precise way than broad immunosuppressants, which could be a meaningful differentiator if clinical benefits and safety hold up. The company also benefits from a sizeable patent estate and regulatory designations that can extend exclusivity in rare lung diseases. However, it operates in indications where large, well‑funded pharmaceutical companies are also active, which raises the competitive bar for clinical efficacy, safety, pricing, and commercial reach. The partnership in Japan helps, but global commercialization would likely require more alliances or significant internal investment.

Innovation and R&D

Innovation and R&D Innovation is the core strength of aTyr. Its platform is built on a novel scientific insight into tRNA synthetases, giving rise to a pipeline of first‑in‑class or highly differentiated candidates. Efzofitimod is in late‑stage development for pulmonary sarcoidosis and is being explored for other interstitial lung diseases, with trial readouts over the next couple of years that will strongly influence the company’s future. Earlier assets like ATYR0101 and ATYR0750 target fibrosis and related pathways with unconventional mechanisms that, if successful, could open entirely new treatment approaches. This strategy offers substantial upside potential but also carries high scientific and clinical risk, as success hinges on validating a relatively unproven area of biology in large, well‑controlled trials.

Summary

aTyr is a small, clinical‑stage biotech with a highly specialized scientific platform and no commercial products yet. Financially, it is pre‑revenue, consistently loss‑making, and reliant on external funding, which is typical for its stage but still a key risk. Strategically, its differentiation comes from pioneering work in tRNA synthetase biology and a lead drug that is approaching pivotal data in serious lung diseases where unmet need remains high. The company’s outlook is tightly linked to upcoming clinical trial results and its ability to secure sufficient capital or partnerships to fund development through potential approval and beyond. This creates a profile that is both opportunity‑rich and risk‑intensive, with outcomes heavily dependent on scientific and regulatory milestones rather than current financial performance.

NEWS

November 29, 2025 · 8:48 AM UTC

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Read more

November 29, 2025 · 7:11 AM UTC

ATYR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR

Read more

November 28, 2025 · 5:40 PM UTC

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

Read more

November 28, 2025 · 12:00 PM UTC

ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Read more

November 27, 2025 · 1:31 PM UTC

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

Read more